Moran Susan 4

What Happened
Susan Moran, a director of Tyra Biosciences (TYRA), was granted a derivative award (option) covering 13,160 shares on May 28, 2026. The Form 4 reports the acquisition price as $0.00 (an award/grant); no cash purchase or sale was reported.

Key Details

• Transaction date: 2026-05-28 (reported on Form 4 filed 2026-06-01). Transaction code: A (award/grant), derivative transaction.
• Shares/options granted: 13,160; acquisition price shown as $0.00 (award). Filing reports the grant as a derivative instrument.
• Shares owned after transaction: not disclosed in the filing.
• Footnote: Grant made under the Issuer's Non-Employee Director Compensation Program. Vesting: 1/12th of the option vests monthly beginning May 28, 2026; if the next annual meeting occurs before the first anniversary, any remaining unvested portion vests on that meeting date, subject to continued service.
• Timeliness: Form 4 filed within the required reporting window (filed June 1, 2026), so not late.

Context
This was a standard director compensation award (an option/derivative grant) rather than a market buy or sale. The award vests monthly over roughly one year (with an acceleration clause tied to the next annual meeting), so the shares/options are not immediately transferable — they vest over time and subject to continued service. Such grants are routine for non-employee directors and represent compensation, not an immediate signal to buy or sell stock.